Get started
Live feed
·
PRReleasevia Quantisnow
Corcept Therapeutics Incorporated logo

Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer

ByQuantisnow·Wall Street's wire, on your screen.
CORTCorcept Therapeutics Incorporated
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CORT (Corcept Therapeutics Incorporated) and more on Quantisnow.